Tivozanib Capsules (Fotivda) is a kinase inhibitor that was first approved in the United States in 2021. As an important drug for the treatment of advanced renal cell carcinoma, it blocks tumor angiogenesis by inhibiting vascular endothelial growth factor receptors.
Indications for Tivozanib Capsules (Fotivda)
Primary Indications
Tivozanib is indicated for the treatment of relapsed or refractory advanced renal cell carcinoma in adults, and patients must have received two or more prior systemic therapies.
Specific applicable populations include:
Relapsed advanced renal cell carcinoma: Refers to patients whose disease progresses again after previous treatment.
Refractory advanced renal cell carcinoma: Refers to patients who have not had an adequate response to prior systemic therapy.
Specifications and Characteristics of Tivozanib Capsules (Fotivda)
0.34 mg Hard Capsules
Capsule Body Feature: Bright yellow and opaque.
Capsule Cap Feature: Bright yellow and opaque.
Marking System: The capsule cap is printed with "TIVZ" in dark blue, and the capsule body is printed with "SD" in dark blue.
0.89 mg Hard Capsules
Capsule Body Feature: Bright yellow and opaque.
Capsule Cap Feature: Dark blue and opaque.
Anti-Counterfeiting Mark: The capsule cap is printed with "TIVZ" in yellow, and the capsule body is printed with "LD" in dark blue.
Both specifications of capsules must be swallowed whole, and can be taken once daily on an empty stomach or with food.
Storage Specifications for Tivozanib Capsules (Fotivda)
Core Storage Conditions
Ideal temperature: 20°C to 25°C (68°F to 77°F).
Allowable fluctuation range: 15°C to 30°C (59°F to 86°F).
Moisture protection: Maintain the tightness of the original packaging at all times.
Key Points for Use and Storage
Storage in original packaging: Keep in the original bottle or blister packaging.
Safety protection: Store in an area out of the reach of children.
Specification for taking: Reseal the container immediately after each use.
